Saxenda is not semaglutide. Saxenda’s active ingredient is liraglutide, a different medication in the same drug class. Both liraglutide and semaglutide are GLP-1 receptor agonists, meaning they mimic the same gut hormone to reduce appetite and promote weight loss. But they are distinct molecules with different dosing schedules, different potency, and different weight loss results.
What Saxenda Actually Contains
Saxenda contains liraglutide, a synthetic version of a natural hormone called GLP-1 that your body releases after eating. This hormone signals fullness to your brain, slows the emptying of your stomach, and helps regulate blood sugar. Liraglutide was originally approved by the FDA in 2010 (under the brand name Victoza) for type 2 diabetes, and later approved as Saxenda specifically for chronic weight management.
Semaglutide, by contrast, is the active ingredient in Wegovy (for weight loss) and Ozempic (for diabetes). Same drug class, different molecule.
How Liraglutide and Semaglutide Differ
The two drugs started from the same foundation but were engineered differently. Liraglutide has a fatty acid chain attached to the GLP-1 molecule that helps it bind to a protein in your blood called albumin, which slows its breakdown and keeps it active long enough for once-daily dosing. Semaglutide took that concept further. Its backbone was modified at a key point to resist an enzyme that normally chews up GLP-1 within minutes, and it uses a longer fatty acid chain with a specialized chemical connector that gives it even stronger albumin binding.
The practical result: liraglutide lasts about a day in your body, so Saxenda is a daily injection. Semaglutide lasts roughly a week, so Wegovy is a once-weekly injection. That single design difference makes semaglutide considerably more convenient for most people.
Weight Loss Results Compared
In the SCALE clinical trials, people taking Saxenda (liraglutide 3.0 mg) lost an average of about 8% of their body weight, compared to roughly 2.6% for those on placebo. That’s a meaningful difference, but semaglutide consistently produces larger results. In the STEP trials for Wegovy, participants typically lost 15% or more of their body weight at the higher maintenance dose, nearly double what Saxenda delivers on average.
Both medications are approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. Saxenda is also approved for adolescents aged 12 and older who meet specific weight criteria.
Side Effects Are Similar but Not Identical
Because both drugs work through the same receptor, they share the same core set of side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. These are the most commonly reported issues with any GLP-1 medication, and they tend to be worst during the dose escalation period before settling down.
That said, semaglutide appears to cause gastrointestinal side effects of greater intensity compared to liraglutide. This makes sense given its stronger potency and longer duration in the body. Both medications use a gradual dose escalation schedule to minimize these effects, but some people tolerate one better than the other.
Dosing and Daily Experience
Saxenda requires a daily subcutaneous injection, typically in the abdomen, thigh, or upper arm. The dose starts low and gradually increases over five weeks to the maintenance dose of 3 mg per day. That means 365 injections per year.
Wegovy (semaglutide) follows a similar escalation principle but on a weekly schedule, reaching its maintenance dose of 2.4 mg after about 16 weeks. That works out to 52 injections per year. For people who dislike needles or struggle with daily medication adherence, the weekly schedule is a significant practical advantage.
Switching From Saxenda to Semaglutide
If you’re currently on Saxenda and considering a switch to Wegovy, the transition isn’t a direct one-to-one swap. The VA’s clinical guidance recommends starting semaglutide at a lower dose (0.5 mg weekly) and gradually titrating up over about 12 weeks to the full 2.4 mg maintenance dose, even if you’ve already been on the maximum Saxenda dose. This cautious approach helps your body adjust to the new medication and reduces the risk of intensified GI side effects. The conversion schedule may also need adjustment depending on individual tolerability.
Cost Differences
Saxenda has a list price of about $1,349 for a 30-day supply. Wegovy’s list price is in a similar range, though actual out-of-pocket costs for both drugs vary widely depending on insurance coverage, manufacturer savings programs, and pharmacy. Neither medication is cheap without assistance, and insurance coverage for weight loss medications remains inconsistent across plans. Checking your specific formulary before committing to either drug can save you from unexpected costs.
Which One Is Right for You
Semaglutide generally produces greater weight loss with less frequent dosing, which is why Wegovy has largely overtaken Saxenda in popularity since its approval. But Saxenda has a longer track record, and some people respond well to it or tolerate it better than semaglutide. Availability also matters: Wegovy has experienced supply shortages that Saxenda has largely avoided. Both are legitimate, FDA-approved options for weight management, and the best choice depends on your body’s response, your insurance situation, and how you feel about daily versus weekly injections.